Selfdiagnostics Deutschland GmbH

SELFDIAGNOSTICS next-generation molecular diagnostics Multitest platform is an innovative tool for launching a family of rapid molecular tests. > MULTITEST COVID-19 https://selfdiagnostics.eu/rapid-pcr-covid-multitest Selfdiagnostics Multitest COVID-19 – the rapid molecular NAAT test combines the ease of use of rapid tests and the diagnostic accuracy of laboratory PCR. ☉ PCR-LEVEL TESTING WITHOUT INVESTMENT. Very straightforward single-use test requires no investment in instruments or infrastructure. No maintenance contracts. No calibration. ☉ UNLIMITED THROUGHPUT. Each test runs independently – there is no need to wait for an instrument to finish the previous test. ☉ EASY AND PORTABLE. Just swab and test – does not require any training. The single-use test is just slightly larger than a credit card. Room temperature stable. A good fit for the following settings: ☉ HOSPITALS to increase rapid PCR testing in emergency departments and on wards immediately without investment in additional instruments. ☉ SMALL CLINICS to have modern PCR testing results without the need to set up a big lab or outsource a PCR testing service. ☉ TESTING SERVICE PROVIDERS to offer rapid PCR results for certificates or immediate diagnostics decisions. ☉ COMPANIES to keep production facilities open by discovering infected individuals reliably and rapidly. MULTITEST LONG-TERM ADVANTAGES: ☉ MASS-PRODUCIBLE. Intentionally simple and minimal component design for cost efficient mass production. Modular production line enables fast production scale-up. ☉ MULTIPLEXED. Able to differentiate up to four different organism’s RNA or DNA from one sample in a single run. Duplex panel test – Selfdiagnostics STD Multitest CT/NG is ready to be launched next after validation. ☉ EXPANDABLE. Has proven multi-sample capability. Tests from swab and urine samples are ready. Expandable to detect from blood, soil and water. IN THE PIPELINE: > MULTITEST STD https://selfdiagnostics.eu/std-multitest